Abstract | BACKGROUND: METHODS: A systematic search of PubMed and EMBASE up until January 19, 2016 was conducted to retrieve prospective studies. The summary risk estimates were pooled using random-effects models. The dose-response relationship was assessed using generalized least-squares trend estimation. RESULTS: Seven nested case-control studies and one prospective cohort study were included in the review. For circulating CRP, women in the highest category had a significantly increased risk of ovarian cancer than women in the lowest category, with no significant between-study heterogeneity [pooled relative risk (RR) = 1.91; 95% confidence intervals (CI) 1.51-2.40; P < 0.001; I(2) = 0.0%]. Influence analyses further supported this positive association. A positive dose-response relationship was also observed (pooled RR = 1.15; 95% CI, 1.03-1.30 per 5 mg/L of CRP). Publication bias was found. However, the association persisted after correction using the trim-and-fill method. No significant association was observed for circulating IL6, TNFα, and soluble TNFR2. CONCLUSION: This meta-analysis provides evidence that elevated levels of CRP, but not circulating IL6, TNFα, or soluble TNFR2, are significantly associated with an increased risk of ovarian cancer. IMPACT: These results suggest that circulating CRP may play a role in the etiology of ovarian cancer. Cancer Epidemiol Biomarkers Prev; 25(8); 1231-9. ©2016 AACR.
|
Authors | Fangfang Zeng, Huishan Wei, Engkiong Yeoh, Zheqing Zhang, Ze-Fang Ren, Graham A Colditz, Shelley S Tworoger, Xuefen Su |
Journal | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
(Cancer Epidemiol Biomarkers Prev)
Vol. 25
Issue 8
Pg. 1231-9
(08 2016)
ISSN: 1538-7755 [Electronic] United States |
PMID | 27277846
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | ©2016 American Association for Cancer Research. |
Chemical References |
- Biomarkers, Tumor
- IL6 protein, human
- Inflammation Mediators
- Interleukin-6
- Receptors, Tumor Necrosis Factor, Type II
- Tumor Necrosis Factor-alpha
- C-Reactive Protein
|
Topics |
- Biomarkers, Tumor
(blood)
- C-Reactive Protein
(analysis)
- Case-Control Studies
- Female
- Humans
- Inflammation Mediators
(blood)
- Interleukin-6
(blood)
- Ovarian Neoplasms
(blood, etiology)
- Prospective Studies
- Receptors, Tumor Necrosis Factor, Type II
(blood)
- Risk
- Tumor Necrosis Factor-alpha
(blood)
|